205 related articles for article (PubMed ID: 34629016)
1. Budget impact of optimizing rifaximin-α use for the prevention of recurrent hepatic encephalopathy in The Netherlands.
de Jong LA; van Schoonhoven AV; Hofstra HS; Postma MJ; van Hoek B
J Med Econ; 2021; 24(1):1149-1163. PubMed ID: 34629016
[TBL] [Abstract][Full Text] [Related]
2. Hospitalizations and healthcare costs associated with rifaximin versus lactulose treatment among commercially insured patients with hepatic encephalopathy in the United States.
Volk ML; Burne R; Guérin A; Shi S; Joseph GJ; Heimanson Z; Ahmad M
J Med Econ; 2021; 24(1):202-211. PubMed ID: 33464935
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the cost-effectiveness of rifaximin-α for the management of patients with hepatic encephalopathy in the United Kingdom.
Berni E; Murphy D; Whitehouse J; Conway P; Di Maggio P; Currie CJ; Poole C
Curr Med Res Opin; 2018 Nov; 34(11):2001-2008. PubMed ID: 29995455
[TBL] [Abstract][Full Text] [Related]
4. Impact of rifaximin use following an initial overt hepatic encephalopathy hospitalization on rehospitalization and costs.
Jesudian AB; Gagnon-Sanschagrin P; Heimanson Z; Bungay R; Chen J; Guérin A; Bumpass B; Borroto D; Joseph G; Dashputre AA
J Med Econ; 2023; 26(1):1169-1177. PubMed ID: 37664993
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness of Rifaximin Treatment in Patients with Hepatic Encephalopathy.
Jesudian AB; Ahmad M; Bozkaya D; Migliaccio-Walle K
J Manag Care Spec Pharm; 2020 Jun; 26(6):750-757. PubMed ID: 32463782
[TBL] [Abstract][Full Text] [Related]
6. Overt Hepatic Encephalopathy: Current Pharmacologic Treatments and Improving Clinical Outcomes.
Rahimi RS; Brown KA; Flamm SL; Brown RS
Am J Med; 2021 Nov; 134(11):1330-1338. PubMed ID: 34242619
[TBL] [Abstract][Full Text] [Related]
7. The cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy - a decision analysis.
Huang E; Esrailian E; Spiegel BM
Aliment Pharmacol Ther; 2007 Oct; 26(8):1147-61. PubMed ID: 17894657
[TBL] [Abstract][Full Text] [Related]
8. Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin.
Neff G; Zachry W
Pharmacoeconomics; 2018 Jul; 36(7):809-822. PubMed ID: 29651649
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of rifaximin versus lactulose for reducing the recurrence of overt hepatic encephalopathy and hopitalizations in cirrhosis.
Irimia R; Trifan A
Rev Med Chir Soc Med Nat Iasi; 2012; 116(4):1021-7. PubMed ID: 23700882
[TBL] [Abstract][Full Text] [Related]
10. Long-term management of hepatic encephalopathy with lactulose and/or rifaximin: a review of the evidence.
Hudson M; Schuchmann M
Eur J Gastroenterol Hepatol; 2019 Apr; 31(4):434-450. PubMed ID: 30444745
[TBL] [Abstract][Full Text] [Related]
11. The impact of rifaximin on the hospital burden and infections in patients with hepatic encephalopathy: a retrospective observational study.
De Graeve J; Vanderstraeten E; Delvaeye T; De Lepeleere S; De Somer T; Van Steenkiste C
Acta Gastroenterol Belg; 2022; 85(3):433-437. PubMed ID: 35833904
[TBL] [Abstract][Full Text] [Related]
12. A Randomized Controlled Trial Comparing the Efficacy of a Combination of Rifaximin and Lactulose with Lactulose only in the Treatment of Overt Hepatic Encephalopathy.
Hasan S; Datta S; Bhattacherjee S; Banik S; Saha S; Bandyopadhyay D
J Assoc Physicians India; 2018 Jan; 66(1):32-6. PubMed ID: 30341842
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Rifaximin Plus Lactulose with the Lactulose Alone for the Treatment of Hepatic Encephalopathy.
Ahire K; Sonawale A
J Assoc Physicians India; 2017 Aug; 65(8):42-46. PubMed ID: 28799305
[TBL] [Abstract][Full Text] [Related]
14. Analysis of hospitalizations comparing rifaximin versus lactulose in the management of hepatic encephalopathy.
Neff GW; Kemmer N; Zacharias VC; Kaiser T; Duncan C; McHenry R; Jonas M; Novick D; Williamson C; Hess K; Thomas M; Buell J
Transplant Proc; 2006 Dec; 38(10):3552-5. PubMed ID: 17175328
[TBL] [Abstract][Full Text] [Related]
15. Targets to improve quality of care for patients with hepatic encephalopathy: data from a multi-centre cohort.
Bajaj JS; O'Leary JG; Tandon P; Wong F; Kamath PS; Biggins SW; Garcia-Tsao G; Lai J; Fallon MB; Thuluvath PJ; Vargas HE; Maliakkal B; Subramanian RM; Thacker LR; Reddy KR
Aliment Pharmacol Ther; 2019 Jun; 49(12):1518-1527. PubMed ID: 31032966
[TBL] [Abstract][Full Text] [Related]
16. Management of hepatic encephalopathy in the hospital.
Leise MD; Poterucha JJ; Kamath PS; Kim WR
Mayo Clin Proc; 2014 Feb; 89(2):241-53. PubMed ID: 24411831
[TBL] [Abstract][Full Text] [Related]
17. Complications of Cirrhosis in Primary Care: Recognition and Management of Hepatic Encephalopathy.
Flamm SL
Am J Med Sci; 2018 Sep; 356(3):296-303. PubMed ID: 30286824
[TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy.
Sharma BC; Sharma P; Lunia MK; Srivastava S; Goyal R; Sarin SK
Am J Gastroenterol; 2013 Sep; 108(9):1458-63. PubMed ID: 23877348
[TBL] [Abstract][Full Text] [Related]
19. Racial and ethnic disparities in rifaximin use and subspecialty referrals for patients with hepatic encephalopathy in the United States.
Tapper EB; Essien UR; Zhao Z; Ufere NN; Parikh ND
J Hepatol; 2022 Aug; 77(2):377-382. PubMed ID: 35367057
[TBL] [Abstract][Full Text] [Related]
20. Rifaximin plus lactulose versus lactulose alone for reducing the risk of HE recurrence.
Sanyal AJ; Kowdley KV; Reau NS; Pyrsopoulos NT; Allen C; Heimanson Z; Bajaj JS
Hepatol Commun; 2024 Jun; 8(6):. PubMed ID: 38727685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
